Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.100 Biomarker group BEFREE A CD117 and CD34 immunoreactive sarcoma masquerading as a gastrointestinal stromal tumor: diagnostic pitfalls of ancillary studies in sarcoma. 21666577 2011
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.100 GeneticVariation group BEFREE KIT and PDGFRA mutations in gastrointestinal stromal tumors) and (ii) sarcomas displaying multiple, complex karyotypic abnormalities with no specific pattern, including leiomyo-sarcoma, and pleomorphic liposarcoma. 20490332 2010
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.100 AlteredExpression group BEFREE The morphologic similarity of uterine mesenchymal tumours and GIST, and the presence of KIT protein in normal uterine tissue, suggests that uterine sarcomas may have the same c-kit overexpression. 17367465 2007
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.100 AlteredExpression group BEFREE Exposure of sarcoma and PDX ovarian carcinoma cells to [pazopanib + entinostat] caused a prolonged activation of ERBB1 and transient/prolonged activations of ERBB2, c-KIT, and c-MET, in a cell-specific fashion. 31380285 2019
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.100 GeneticVariation group BEFREE Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas. 17298867 2007
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.100 GeneticVariation group BEFREE Gastrointestinal stromal tumors (GIST) are the most common adult sarcomas and the oncogenic driver is usually a KIT or PDGFRA mutation. 25836719 2015
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.100 GeneticVariation group BEFREE The identification of activating KIT mutations in the majority of GISTs was a defining moment that led to the first effective targeted therapy for sarcoma, and the subsequent use of imatinib mesylate has revolutionized the treatment of GISTs. 22055970 2011
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.100 GeneticVariation group BEFREE During this period, this distinct disease entity was identified under various acronyms (GIST remaining the most commonly used), the molecular basis of disease transformation (i.e. activating c-KIT mutations) was identified in sporadic and familial cases, and finally GIST was identified as the sarcoma subtype most resistant to chemotherapy in both retrospective and prospective studies. 14657591 2003
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.100 GeneticVariation group BEFREE KIT mutation in gastrointestinal stromal tumours); and (i) sarcomas with non-specific genetic alterations and complex unbalanced karyotypes. 16359533 2006
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.100 GeneticVariation group BEFREE Furthermore, the determination of the relationship of specific KIT mutations and sensitivity and resistance to kinase-directed agents and the assessment of inhibitor levels and the quality of response to those agents have implications beyond the treatment of sarcomas. 19664491 2009
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.100 GeneticVariation group BEFREE Gastrointestinal stromal tumor (GIST) is the most common human sarcoma and typically results from an activating mutation in the KIT oncogene. 24323358 2013
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.100 Biomarker group BEFREE The most common mutation was in the ret proto-oncogene, which occurred in 47 cases followed by mutations in genes encoding Harvey rat sarcoma viral oncogene homolog (N = 14), serine/threonine kinase 11 (N = 11), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (N = 6), mutL homolog 1 (N = 4), Kiesten rat sarcoma viral oncogene homolog (N = 3) and MET proto-oncogene (N = 3). 26295973 2015
Entrez Id: 3815
Gene Symbol: KIT
KIT
0.100 Biomarker group BEFREE <b>Purpose:</b> A phase Ib study of dasatinib plus ipilimumab in patients with gastrointestinal stromal tumor (GIST) and other sarcomas was performed on the basis of preclinical data demonstrating that combined KIT and CTLA-4 blockade is synergistic.<b>Experimental Design:</b> A standard 3 + 3 design was used to evaluate the safety, efficacy, and immune correlates of treatment. 28007774 2017